Omeprazole in Pediatrics: FDA-Approved Indications and Age Groups
Yes, omeprazole is FDA-indicated for pediatric patients aged 2-16 years for specific gastroesophageal reflux disease (GERD) conditions, but NOT for infants under 2 years of age or for simple reflux without complications. 1
FDA-Approved Pediatric Indications
According to the FDA drug label, omeprazole is approved for children 2 to 16 years old for the following conditions 1:
- Treatment of symptomatic GERD (up to 4 weeks)
- Treatment of erosive esophagitis (EE) due to acid-mediated GERD (4-8 weeks)
- Maintenance of healing of EE (controlled studies do not extend beyond 12 months)
Weight-Based Dosing 1:
- 10-20 kg: 10 mg once daily
- ≥20 kg: 20 mg once daily
- Dose range: 0.7-3.3 mg/kg/day 2
Critical Age Restrictions
Omeprazole is NOT FDA-approved for:
This is particularly important because the American Academy of Pediatrics guidelines explicitly warn against PPI overuse in infants, noting that placebo-controlled trials in infants have not demonstrated superiority of PPIs over placebo for reduction in irritability 2.
When to Use vs. When NOT to Use
DO USE omeprazole when 2:
- Documented erosive esophagitis on endoscopy
- Severe GERD symptoms (heartburn, epigastric pain in older children) that persist despite lifestyle modifications
- GERD refractory to H2-receptor antagonists
- Age ≥2 years with appropriate weight-based dosing
DO NOT USE omeprazole when 2, 4:
- Simple regurgitation/spitting up in infants (physiologic GER)
- Chronic cough without gastrointestinal symptoms - multiple guidelines strongly recommend against empirical GERD treatment in children with isolated chronic cough 4
- Irritability alone in infants - no proven benefit over placebo 2
- Age <2 years unless absolutely necessary with specialist consultation
Important Safety Considerations
Risks in Young Children 2:
- Increased risk of community-acquired pneumonia
- Increased risk of gastroenteritis
- Increased risk of candidemia
- Necrotizing enterocolitis in preterm infants
- Enterochromaffin cell hyperplasia (up to 50% of children receiving PPIs >2.5 years)
- Bone effects in animal studies (decreased femur length, cortical bone thickness)
Common Adverse Effects 2:
- Headaches (up to 14%)
- Diarrhea
- Constipation
- Nausea
Clinical Algorithm for Decision-Making
For children 2-16 years with suspected GERD:
- Assess for alarm symptoms (dysphagia, weight loss, GI bleeding) → if present, consider endoscopy before treatment
- Try lifestyle modifications first (positioning, dietary changes, smaller meals)
- If symptoms persist and are severe:
- Consider H2-receptor antagonist trial first (ranitidine, famotidine) 2
- If inadequate response after 2-4 weeks → switch to PPI
- Reserve PPIs for:
- Endoscopically-proven erosive esophagitis
- Severe symptoms unresponsive to H2RAs
- Documented pathologic acid reflux on pH monitoring
For infants <2 years:
- Reassurance and education - most infant reflux is physiologic and self-limiting 2
- Thickened feeds if needed for regurgitation
- Avoid empirical PPI therapy - not FDA-approved and evidence shows no benefit for irritability 2
- Only consider acid suppression if:
- Documented erosive esophagitis on endoscopy
- Failure to thrive with proven GERD
- After specialist consultation
Key Pitfalls to Avoid
The most common error is overprescribing PPIs in infants with normal physiologic reflux. Studies show inappropriate use in 61.5% of noncritically ill pediatric patients 5. The dramatic increase in PPI prescriptions for infants is a matter of "great concern" according to AAP guidelines, particularly given the lack of efficacy data and emerging safety concerns 2.
For chronic cough: Do not use empirical GERD treatment unless typical GERD symptoms (regurgitation, heartburn) are present - this is a Grade 1B strong recommendation 4.
Duration matters: If PPIs are used, reassess need regularly. Most studies show efficacy for 4-8 weeks; long-term use beyond 12 months lacks safety data in children 1.